Search

Author

Subject

Date issued

Has File(s)

Search Results

Results 71-80 of 384 (Search time: 0.004 seconds).
    • Novel insights into congenital surfactant dysfunction disorders by in silico analysis of ABCA3 proteins
    Authors: Guo-Liang, Xiao; Yuan, Gao; Hu, Hao;  Advisor: -;  Co-Author: - (2023)

    Surfactants produced by type II alveolar epithelial cells (AT2 cells) are usually present in inclusion organelles called lamellar bodies (LBs). The ATP-binding cassette subfamily A member 3 (ABCA3) transporter primarily exists in AT2 cells and is generally considered to be one of the critical regulators of biogenesis of LBs and surfactant metabolism in the lungs [1,2,3,4]. ABCA3 mutations are the most common cause of congenital surfactant dysfunction disorders (CSDDs), resulting in fatal neonatal respiratory distress and pediatric or adult interstitial lung disease [3, 5,6,7].
    • Impact of renal replacement therapy strategy on beta-lactam plasma concentrations: the BETAKIKI study—an ancillary study of a randomized controlled trial
    Authors: Damien, Roux; Nicolas, Benichou; David, Hajage;  Advisor: -;  Co-Author: - (2023)

    Sepsis prognosis correlates with antibiotic adequacy at the early phase. This adequacy is dependent on antibacterial spectrum, bacterial resistance profile and antibiotic dosage. Optimal efficacy of beta-lactams mandates concentrations above the minimal inhibitory concentration (MIC) of the targeted bacteria for the longest time possible over the day. Septic acute kidney injury (AKI) is the most common AKI syndrome in ICU and often mandates renal replacement therapy (RRT) initiation. Both severe AKI and RRT may increase outside target antibiotic concentrations and ultimately alter patient’s prognosis.
    • Inhaler Technique Questionnaire (InTeQ) in pediatric patients with asthma
    Authors: Catalina, Lizano-Barrantes; Olatz, Garin; Alexandra Lelia, Dima;  Advisor: -;  Co-Author: - (2023)

    The InTeQ has proven to be feasible, valid, and reliable in adults with persistent asthma [16], which can be useful for patients’ self-monitoring and healthcare professionals teaching patients. This study aimed to assess the InTeQ’s validity and reliability in children and adolescents with asthma. This study was performed within the ARCA (Asthma Research in Children and Adolescents) cohort, a prospective, multicenter, observational study (NCT04480242) [17], replicating the original InTeQ validation performed on adults with asthma [16]
    • Targeting circulating high mobility group box-1 and histones by extracorporeal blood purification as an immunomodulation strategy against critical illnesses
    Authors: Yupei, Li; Yu, Chen; Tinghang, Yang;  Advisor: -;  Co-Author: - (2023)

    Both high mobility group box-1 (HMGB1) and histones are major damage-associated molecular patterns (DAPMs) that mediate lethal systemic inflammation, activation of the complement and coagulation system, endothelial injury and multiple organ dysfunction syndrome in critical illnesses. Although accumulating evidence collectively shows that targeting HMGB1 or histones by their specific antibodies or inhibitors could significantly mitigate aberrant immune responses in multiple critically ill animal models, routine clinical use of such agents is still not recommended by any guideline.
    • Sodium-glucose cotransporter 2 inhibitor-associated perioperative ketoacidosis: a systematic review of case reports
    Authors: Hiroyuki, Seki; Satoshi, Ideno; Toshiya, Shiga;  Advisor: -;  Co-Author: - (2023)

    Although the recommended preoperative cessation period for sodium-glucose cotransporter 2 inhibitors (SGLT2is) changed in 2020 (from 24 h to 3–4 days preoperatively) to reduce the risk of SGLT2i-associated perioperative ketoacidosis (SAPKA), the validity of the new recommendation has not been verified. Using case reports, we assessed the new recommendation effectiveness and extrapolated precipitating factors for SAPKA. We searched electronic databases up to June 1, 2022 to assess SAPKA (blood pH < 7.3 and blood or urine ketone positivity within 30 days postoperatively in patients taking SGLT2i).
    • Sepsis-related coagulopathy treatment based on the disseminated intravascular coagulation diagnostic criteria a post-hoc analysis of a prospective multicenter observational study
    Authors: Takeshi, Wada; Kazuma, Yamakawa; Daijiro, Kabata;  Advisor: -;  Co-Author: - (2023)

    The development of disseminated intravascular coagulation (DIC) in patients with sepsis has been repeatedly confirmed as a factor associated with poor prognosis. Anticoagulant therapy has been expected to improve sepsis patient outcomes, whereas no randomized controlled trials have demonstrated the survival benefit of anticoagulant therapies in non-specific overall sepsis. Patient selection based on the component of “high disease severity” in addition to “sepsis with DIC” has recently proved important in identifying appropriate targets for anticoagulant therapy. The aims of this study were to characterize “severe” sepsis DIC patients and to identify the patient population benefiting from anticoagulant therapy.